Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 100Gastrointestinal 50Breast 42Thoracic 41Genitourinary 36Head & Neck 28Dermatologic 28Other solid neoplasm 8Sarcoma 7Lymphoid 6CNS 4Plasma cell 2Other hematologic neoplasm 2Endocrine 2NET 1

Conditions

Multiple Myeloma 27Hodgkin Disease 3Breast Neoplasms 3Recurrence 2Ovarian Neoplasms 2Neoplasms 2Myeloproliferative Disorders 2Myelodysplastic Syndromes 2Lymphoma, Non-Hodgkin 2Lymphoma, Follicular 2Lung Neoplasms 2Leukemia, Lymphocytic, Chronic, B-Cell 2Waldenstrom Macroglobulinemia 1Urogenital Neoplasms 1Triple Negative Breast Neoplasms 1Thrombocytosis 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Smoldering Multiple Myeloma 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Myelodysplastic-Myeloproliferative Diseases 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Myelomonocytic, Chronic 1

Interventions

Cyclophosphamide 6fludarabine 4Magnetic Resonance Spectroscopy 3Flow Cytometry 3trametinib 2pembrolizumab 2liposomal doxorubicin 2dabrafenib 2aldesleukin 2Specimen Handling 2Methylprednisolone 2Immunologic Techniques 2Gemcitabine 2Dexamethasone 2Biopsy 2Azacitidine 2Alemtuzumab 2ulixertinib 1trastuzumab biosimilar HLX02 1sargramostim 1saracatinib 1sapanisertib 1ruxolitinib 1rucaparib 1resiquimod 1relatlimab 1poly ICLC 1pertuzumab 1palbociclib 1osimertinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Ovarian Neoplasms × pembrolizumab × Plasma cell × Clear all
NCT03412877 2026-05-22

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
285 enrolled
BreastEndocrineGynecologicNETPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Multiple Myeloma, Ovarian Neoplasms, Urogenital Neoplasms, Neuroendocrine Tumors

NCT04354246 2026-05-12

COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies

Compugen Ltd

Phase 1 Completed
94 enrolled
GastrointestinalGynecologicHead & NeckPlasma cellThoracic

Squamous Cell Carcinoma of Head and Neck, Colonic Neoplasms, Lung Neoplasms, Multiple Myeloma, Ovarian Neoplasms, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡